UNIverse - Public Research Portal
Project cover

Pharmacological antiemetic prophylaxis and treatment for opioid induced nausea and vomiting (OINV) in patients treated for cancer pain: Cochrane systematic review

Research Project
 | 
01.11.2024
 - 31.10.2026

Background:

In cancer patients with incurable disease pain is one of the most debilitating symptoms with a prevalence of about 70% (1). Many of these patients need opioids, which are the mainstay in managing cancer pain. Initiation of opioid therapy is frequently hindered by opioid induced nausea and vomiting (OINV) in up to 40% of patients (2). Nausea is highly distressing symptom that may occur with or without vomiting and can affect overall outcome and quality of life (3). To avoid discontinuation of the opioid therapy 50-80% of doctors prescribe prophylactic or on-demand antiemetics to reduce OINV (4), although evidence for this practice is scarce or not supported by randomised controlled trials (RCTs) (5). However, the medications used to prevent OINV, e.g. dopamine antagonists can trigger adverse events in the central nervous system (headaches, drowsiness) or even parkinsonism-like symptoms.

 Aims / Methods:

To better inform physicians, guidelines and patients, we propose a Cochrane systematic review and meta-analysis of RCTs concerning the benefits and harms of antiemetic drug therapy for the prevention and treatment of OINV in patients treated with opioids for cancer pain therapy.

Benefit for patients and / or public

The numbers of affected patients are expected to increase during the decades to come due to the medical progress in oncology and the demographic change (9,10).


Members (6)

MALE avatar

Christian Appenzeller-Herzog

Search
Profile Photo

Christopher Böhlke

Owner
MALE avatar

Jan Gärtner

Profile Photo

Katja Suter-Zimmermann

Pharmacist
MALE avatar

Guido Schwarzer

Statistician
MALE avatar

Vanessa Piechotta

Cochrane methodologist